These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 18458271)

  • 41. [Treatment with hydroxyurea has revolutionized the evolution of sickle cell disease ].
    Bartolucci P; de Montalembert M
    Rev Prat; 2014 Oct; 64(8):1127-8. PubMed ID: 25510141
    [No Abstract]   [Full Text] [Related]  

  • 42. Hydroxyurea for Sickle Cell Disease: Now Is the Time!
    Strouse JJ
    South Med J; 2016 Sep; 109(9):535-7. PubMed ID: 27598356
    [No Abstract]   [Full Text] [Related]  

  • 43. Long-term use of hydroxyurea for sickle cell anemia.
    Lee DA; Mueller BU
    JAMA; 2003 Aug; 290(6):753-4; author reply 754. PubMed ID: 12915425
    [No Abstract]   [Full Text] [Related]  

  • 44. Long-term hydroxyurea treatment in young sickle cell patients.
    Maier-Redelsperger M; Labie D; Elion J
    Curr Opin Hematol; 1999 Mar; 6(2):115-20. PubMed ID: 10088642
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease.
    Mahadeo KM; Oyeku S; Taragin B; Rajpathak SN; Moody K; Santizo R; Driscoll MC
    Am J Hematol; 2011 Sep; 86(9):806-8. PubMed ID: 21850660
    [No Abstract]   [Full Text] [Related]  

  • 46. Treatment adherence in patients with sickle cell anemia.
    Drotar D
    J Pediatr; 2010 Mar; 156(3):350-1. PubMed ID: 20056235
    [No Abstract]   [Full Text] [Related]  

  • 47. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 48. Experts urge wider use of hydroxyurea for sickle cell disease.
    Traynor K
    Am J Health Syst Pharm; 2008 Apr; 65(7):592-3. PubMed ID: 18359960
    [No Abstract]   [Full Text] [Related]  

  • 49. Hydroxyurea and new agents for the treatment of sickle cell disease.
    Rodgers GP
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):713-5. PubMed ID: 16163257
    [No Abstract]   [Full Text] [Related]  

  • 50. Improving Uptake of Hydroxyurea in Patients with Sickle Cell Disease: A Retrospective Study of a Clinic-based Change in Consenting Practices.
    Smith AW; Bodas P; Sidebotham L; Weilnau J; Wildman B
    J Natl Med Assoc; 2019 Apr; 111(2):169-175. PubMed ID: 30314826
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hydroxyurea for ALL children with sickle cell anemia: What can we learn from Africa?
    Aygun B
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28164. PubMed ID: 31925887
    [No Abstract]   [Full Text] [Related]  

  • 52. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea.
    Wilson S
    Ann Intern Med; 2000 Dec; 133(11):925-6. PubMed ID: 11103075
    [No Abstract]   [Full Text] [Related]  

  • 53. Hydroxyurea, sickle cell disease and renal transplantation.
    Allen A; Scoble J; Snowden S; Hambley H; Bellingham A
    Nephron; 1997; 75(1):106-7. PubMed ID: 9031282
    [No Abstract]   [Full Text] [Related]  

  • 54. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
    Dong M; Mizuno T; Vinks AA
    Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of hydroxyurea on clinical events in the BABY HUG trial.
    Thornburg CD; Files BA; Luo Z; Miller ST; Kalpatthi R; Iyer R; Seaman P; Lebensburger J; Alvarez O; Thompson B; Ware RE; Wang WC;
    Blood; 2012 Nov; 120(22):4304-10; quiz 4448. PubMed ID: 22915643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term use of hydroxyurea for sickle cell anemia.
    Feldman L; Allen S; Westerman M; Feldman L; Gilman-Sachs A; Beaman K
    JAMA; 2003 Aug; 290(6):752-3; author reply 754. PubMed ID: 12915423
    [No Abstract]   [Full Text] [Related]  

  • 58. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
    Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
    Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea.
    Stettler N; McKiernan CM; Melin CQ; Adejoro OO; Walczak NB
    JAMA; 2015 Apr; 313(16):1671-2. PubMed ID: 25919532
    [No Abstract]   [Full Text] [Related]  

  • 60. Hydroxyurea use in patients with sickle cell disease in a Medicaid population.
    Ritho J; Liu H; Hartzema AG; Lottenberg R
    Am J Hematol; 2011 Oct; 86(10):888-90. PubMed ID: 21922530
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.